Evotec AG today announced a novel strategic partnership with the University of Oxford, Oxford University Innovation Ltd, OUI (the university’s research commercialisation company) and Oxford Sciences Innovation, OSI (the world’s largest IP investment company dedicated to a single university) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-oxford-create-novel-partnership-called-lab282-5408
Evotec AG reports results of first nine months of 2016
Evotec AG today reported financial results and corporate updates for the first nine months of 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-nine-months-of-2016-5410
Evotec announces its intent to acquire Cyprotex PLC
Evotec AG today announced that it has made an offer to acquire Cyprotex PLC („Cyprotex“, AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-its-intent-to-acquire-cyprotex-plc-5404
Ad hoc: Evotec AG announces its intent to acquire Cyprotex PLC
Evotec AG today announced that it has made an offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in UK. The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-announces-its-intent-to-acquire-cyprotex-plc-5626
Evotec and UCB sign multi-year CNS pharmacology agreement
Evotec AG today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ucb-sign-multi-year-cns-pharmacology-agreement-5402
Evotec and Carrick Therapeutics build strategic alliance
Evotec AG announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-carrick-therapeutics-build-strategic-alliance-5398
Evotec receives further important pre-clinical milestone in endometriosis alliance with Bayer
Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another key pre-clinical milestone for the transition of a project from the alliance portfolio into pre-clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-further-important-pre-clinical-milestone-in-endometriosis-alliance-with-bayer-5396
Evotec enters into strategic multi-target alliance with C4X Discovery
Evotec AG today announced a multi-target collaboration with C4X Discovery Holdings plc („C4XD“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-strategic-multi-target-alliance-with-c4x-discovery-5394
Evotec enters into a research collaboration with Inserm in oncology
Evotec AG announced today that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research („Inserm“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-a-research-collaboration-with-inserm-in-oncology-5392
Evotec and Bayer partner to develop new treatments to fight kidney diseases
Evotec AG today announced that Evotec and Bayer have entered into a five-year, multi-target research partnership in kidney disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-partner-to-develop-new-treatments-to-fight-kidney-diseases-5387